Goldman Sachs raised the firm’s price target on Glaukos (GKOS) to $153 from $134 and keeps a Buy rating on the shares. Glaukos reported strong Q1 results with revenue and forward guidance both exceeding already elevated expectations, driven by accelerating adoption of iDose and early traction from the newly launched EpiOxa product, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target raised to $136 from $127 at Needham
- Glaukos price target raised to $141 from $131 at BTIG
- Glaukos price target raised to $140 from $135 at Citi
- Glaukos Reaffirmed as Buy on Strong Q1 Beat, Raised 2026 Revenue Outlook, and Billion-Dollar Peak Potential for iDose and Epioxa
- Glaukos reports Q1 EPS (18c), consensus (28c)